5th Annual ALS Drug Development Summit

The 5th ALS Drug Development Summit 2026 is a specialised scientific conference focused on advancing drug discovery and development for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Scheduled for June 2–4, 2026 at The Colonnade in Boston, Massachusetts, USA, the summit unites the global ALS research and development community—including biotech innovators, pharmaceutical companies, academic researchers, patient advocacy groups and regulatory experts—to share the latest mechanistic insights, therapeutic strategies and clinical development best practices. With dedicated tracks spanning early discovery through clinical and regulatory design, the event offers a comprehensive program of data-driven presentations, panel discussions and workshops aimed at addressing disease heterogeneity, biomarker strategy, trial optimisation, and patient-centric development. The 2026 summit features more than 30 confirmed speakers from leading pharmaceutical and biotech organisations, offering diverse perspectives on current and emerging ALS therapeutic strategies. Presenters include Arti Patel (Principal Scientist, Novartis), Christian Rubio (Executive Director, EverythingALS), Irina Antonijevic (Chief Medical Officer, Trace Neuroscience), Shih-Ching (Joyce) Lo (Associate Director, Biogen), Kelly Glajch (Scientific Director, Takeda), Michael Hayden (CEO, Prilenia Therapeutics), and Philip C. Wong (Professor, Johns Hopkins Medicine), with discussions spanning spatial omics, advanced models, adaptive trial design and patient engagement. Alongside the depth of scientific content, the event provides extensive networking and collaboration opportunities with over 100 senior experts and participating companies such as Biogen, Eli Lilly, Novartis, AbbVie, Takeda, Mitsubishi Tanabe Pharma, uniQure, QurAlis and Sanofi, creating a vital forum for shaping the next generation of ALS and FTD therapies.